India Anti-fungal Drugs Market Report: Size, Share, Growth and Forecast 2025-2033
India Anti-fungal Drugs Market Overview
The India anti-fungal drugs market size reached USD 509.90 Million in 2024. The market is projected to grow at a CAGR of 3.10% during the forecast period from 2025 to 2033, reaching a value of USD 671.14 Million by 2033. The expanding market is driven primarily by the rising incidence of diabetes, creating favorable conditions for fungal infections and improved access to treatment in healthcare facilities. The report presents a thorough review featuring the India anti-fungal drugs market report, growth, share, trends, and research of the industry.
India Anti-fungal Drugs Market Study Assumption Years
- Base Year : 2024
- Historical Year/Period : 2019-2024
India Anti-fungal Drugs Market Key Takeaways
- Current Market Size : USD 509.90 Million
- CAGR : 3.10%
- Forecast Period : 2025-2033
- The India anti-fungal drugs market is expanding due to increased diabetes incidence, a condition that supports fungal growth.
- Rising diagnosis and treatment access in hospitals, clinics, and diagnostic centers bolster market growth.
- Growing awareness among patients and healthcare providers emphasizes regular fungal infection screening.
- Improvements in healthcare infrastructure and increased funding facilitate wider antifungal drug reach.
- Newer and more effective antifungal drugs are becoming available due to investments in R&D.
Sample Request Link : [https://www.imarcgroup.com/india-anti-fungal-drugs-market/requestsample
India Anti-fungal Drugs Market Growth Factors
The growth in the Indian anti-fungal drugs market is also attributed to the increasing prevalence of diabetes in the country. Diabetic individuals are very prone to oral thrush, fungal toenail, vaginal candidiasis and mucormycosis, as per the data provided here. Increased blood glucose and decreased immunity cause fungal overgrowth, which in turn creates increased demand, for antifungal medication.
Poorly controlled diabetes may ease a more severe and recurrent infection and require longer antifungal therapy. Furthermore, most of the diabetic patients are also frequently given broad-spectrum antibiotics or steroids that may increase secondary fungal infections by disturbing the microbial flora of the respiratory tract, digestive tract, and vagina. This is resulting in increased awareness of the increased risk of infection in diabetic patients, who are being prescribed and using antifungal medications.
Construction of more healthcare infrastructure could also be a factor: the government's increased expenditure for the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission infrastructure seeks to develop primary and secondary healthcare facilities in underdeveloped areas. Increasing diagnosis and treatment of undiagnosed and untreated fungal infections and the increase in antifungal drug consumption are expected to drive the growth of the market. Furthermore, the increasing number of specialized dermatology and infectious disease clinics for the treatment of fungal infections is expected to increase growth.
India Anti-fungal Drugs Market Trends
The India anti-fungal drugs market is expected to see big growth during the forecast period because the type 2 diabetes mellitus (T2DM) population is growing. The International Diabetes Federation projects the T2DM population will increase to around 134 million by 2045, risking acquisition and development of several fungal diseases in consequence, which may cause increased anti-fungal drug use at hospitals.
Furthermore, government involvement in health care has resulted in greater access to diagnosis and treatment through public funding of construction of healthcare infrastructure like health care facilities and specialized clinics, and increased availability of antifungal medications.
There is an increasing need for new antifungals to be placed on the market as well as antifungal R&D. More affordable antifungal therapies, such as azole antifungals which are available for less, are in increasing demand due to their economic and therapeutic value compared to standard antifungal therapies.
The rising incidence of secondary fungal infections due to increased use of antibiotics and steroids to treat conditions such as diabetes and COVID-19 complications is also expected to reinforce growth of this segment in the hospital and pharmacy channels.
These trends are further demonstrative of the well-documented expansion and evolution of the India anti-fungal drugs market.
Buy the Full Report for Complete Data, Trends, and Opportunities: https://www.imarcgroup.com/checkout?id=31384&method=1337
India Anti-fungal Drugs Market Segmentation
Drug Class Insights: Azoles, Echinocandins, Polyenes, Allylamines, Others
- The market includes these major drug classes, offering a variety of antifungal treatment options.
Indication Insights: Candidiasis, Aspergillosis, Dermatophytosis, Mucormycosis, Others
- Antifungal drugs are utilized across these key fungal infection indications prevalent in India.
Infection Type Insights: Superficial Fungal Infection, Systemic Fungal Infection
- Treatment segmentation is based on infection type affecting skin or systemic organs.
Route of Administration Insights: Parenteral, Topical, Oral, Others
- The market features multiple administration routes catering to different patient needs and infection severities.
Distribution Channel Insights: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
- Antifungal drugs are distributed through traditional and digital pharmacy channels.
End User Insights: Homecare, Hospitals and Clinics, Others
- The end-user base spans homecare settings to healthcare institutions and other facilities.
India Anti-fungal Drugs Market Regional Insights
- North India
- South India
- East India
- West India
The India anti-fungal drugs market is dominated by South India, holding a significant market share with a sustained CAGR of 3.10%. This regional prominence is supported by robust healthcare infrastructure and high demand for antifungal treatments.
India Anti-fungal Drugs Market Key Players
The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.
India Anti-fungal Drugs Market Recent Developments & News
In August 2024, researchers from Agharkar Research Institute under the Indian Department of Science & Technology developed Nikkomycin-loaded polymeric nanoparticles derived from Streptomyces spp. These nanoparticles effectively inhibited Aspergillus spp growth, demonstrating efficacy against aspergillosis.
In September 2023, BDR Pharmaceutical launched Zisavel capsules, an azole antifungal drug for invasive aspergillosis and mucormycosis treatment. This medication is priced at one-third the cost of existing options in the Indian market, enhancing treatment affordability and accessibility.
India Anti-fungal Drugs Market Key Highlights of the Report
- Comprehensive quantitative analysis of market segments, historical trends, and forecast from 2019 to 2033.
- Detailed insights into market drivers, challenges, and opportunities.
- In-depth segmentation analysis by drug class, indication, infection type, route of administration, distribution channel, and end user.
- Porter’s five forces analysis to assess industry competitiveness and market attractiveness.
- Thorough competitive landscape including key player profiling and strategic assessment.
Get Your Customized Market Report Instantly: https://www.imarcgroup.com/request?type=report&id=31384&flag=E
Customization Note: If you require any specific information not covered within this report’s scope, we will provide it as part of the customization.
About Us
IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel: (D) +91 120 433 0800
United States: +1-201971-6302